AIDED - Acute kIDnEy injury in coviD-19.
- Funded by UK Research and Innovation (UKRI)
- Total publications:2 publications
Grant number: MR/V037005/1
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$133,357.77Funder
UK Research and Innovation (UKRI)Principal Investigator
Professor Susan FrancisResearch Location
Sweden, United KingdomLead Research Institution
University of NottinghamResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Other
Occupations of Interest
Unspecified
Abstract
The pandemic caused by the Coronavirus (COVID-19) although primarily affecting the lungs and airways, affects other organs in the body. At least a quarter of people who need hospital treatment for COVID-19 also suffer reduced kidney function (known as acute kidney injury, AKI), which can cause complete kidney failure. As some of the processes that lead to AKI in COVID-19 are specific to the viral infection, it is possible that long term kidney health may be more severely affected. At the moment, we do not know the long-term effects of COVID-19 on the kidneys. Improving our understanding of this is important to allow us to know how best to monitor and support people after their recovery from the initial infection. To address this, we will perform a unique research study that will bring together scientists at the University of Nottingham, UK and those in Uppsala University, Sweden. The study will collect a number of different Magnetic Resonance Imaging (MRI) datasets in ventilated patients with acute COVID-19 in Uppsala University (UU), Sweden. MRI can show the entire kidney in great detail and there is a range of MRI techniques that can assess different aspects of kidney function. Combining the different MRI techniques into a single scan session is called multiparametric MRI. Multiparametric MRI will assess the changes that may have been caused by COVID-19 in the kidneys, such as changes in blood flow, oxygen levels and the degree of scarring (fibrosis). In addition, changes in other organ function such as the liver and spleen will be measured. Importantly, MRI scans do not use radiation (unlike X-Rays and CT scans). Patients scanned at the acute phase of COVID-19 will have their MRI measures collected again at 3 and 12 months after being in hospital. The multiparametric MRI measures collected in Sweden will be analysed by experts at UoN and compared to an existing MRI dataset of non-COVID AKI collected at the UoN, prior to the COVID-19 outbreak, and healthy subjects from both the UoN and UU. These information sources will allow us to understand the long-term effects of COVID-19 on the kidneys. This will inform how COVID-19 is impacting patients' kidney health, and how this should be monitored.
Publicationslinked via Europe PMC
Last Updated:2 days ago
View all publications at Europe PMC